Bardina V[au] - Search Results

Year	Number of Results
2011	1
2013	1
2014	1
2015	1
2016	3
2017	4
2018	1
2019	1
2022	1

1

Natalizumab in Multiple Sclerosis: Long-Term Management.

Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L. Clerico M, et al. Among authors: bardina v. Int J Mol Sci. 2017 Apr 29;18(5):940. doi: 10.3390/ijms18050940. Int J Mol Sci. 2017. PMID: 28468254 Free PMC article. Review.

2

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.

Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L. Clerico M, et al. Among authors: bardina v. Expert Opin Drug Saf. 2017 Aug;16(8):963-972. doi: 10.1080/14740338.2017.1346082. Epub 2017 Jul 5. Expert Opin Drug Saf. 2017. PMID: 28641055 Free article. Review.

3

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis.

Iannello A, Rolla S, Maglione A, Ferrero G, Bardina V, Inaudi I, De Mercanti S, Novelli F, D'Antuono L, Cardaropoli S, Todros T, Turrini MV, Cordioli C, Puorro G, Marsili A, Lanzillo R, Brescia Morra V, Cordero F, De Bortoli M, Durelli L, Visconti A, Cutrupi S, Clerico M. Iannello A, et al. Among authors: bardina v. Front Immunol. 2019 Jan 8;9:3075. doi: 10.3389/fimmu.2018.03075. eCollection 2018. Front Immunol. 2019. PMID: 30671056 Free PMC article.

4

Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.

Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F, Clerico M. Rolla S, et al. Among authors: bardina v. J Leukoc Biol. 2014 Dec;96(6):1155-64. doi: 10.1189/jlb.5A0813-463RR. Epub 2014 Aug 5. J Leukoc Biol. 2014. PMID: 25097195

5

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M. De Mercanti S, et al. Among authors: bardina v. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 26819963 Free PMC article.

6

Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, Cocco E, Annovazzi P, Vladic A, Novelli F, Durelli L, Clerico M. Rolla S, et al. Among authors: bardina v. J Neuroimmunol. 2017 Dec 15;313:89-91. doi: 10.1016/j.jneuroim.2017.10.009. Epub 2017 Oct 17. J Neuroimmunol. 2017. PMID: 29153614 Free article.

7

The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice.

Rolla S, Alchera E, Imarisio C, Bardina V, Valente G, Cappello P, Mombello C, Follenzi A, Novelli F, Carini R. Rolla S, et al. Among authors: bardina v. Clin Sci (Lond). 2016 Feb;130(3):193-203. doi: 10.1042/CS20150405. Epub 2015 Nov 11. Clin Sci (Lond). 2016. PMID: 26558403

8

Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity.

Alchera E, Rolla S, Imarisio C, Bardina V, Valente G, Novelli F, Carini R. Alchera E, et al. Among authors: bardina v. Transl Res. 2017 Apr;182:75-87. doi: 10.1016/j.trsl.2016.11.009. Epub 2016 Dec 6. Transl Res. 2017. PMID: 28011152

9

Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development.

Rolla S, Ingoglia G, Bardina V, Silengo L, Altruda F, Novelli F, Tolosano E. Rolla S, et al. Among authors: bardina v. J Immunol. 2013 Dec 1;191(11):5451-9. doi: 10.4049/jimmunol.1203076. Epub 2013 Oct 23. J Immunol. 2013. PMID: 24154625 Free article.

10

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up.

Rolla S, De Mercanti SF, Bardina V, Maglione A, Taverna D, Novelli F, Cocco E, Vladic A, Habek M, Adamec I, Annovazzi POL, Horakova D, Clerico M. Rolla S, et al. Among authors: bardina v. Front Immunol. 2022 Feb 28;13:818325. doi: 10.3389/fimmu.2022.818325. eCollection 2022. Front Immunol. 2022. PMID: 35296069 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results